At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 597 enrolled
Drug / intervention
Bimatoprost 0.03% Formulation B Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Bimatoprost 0.03% Formulation B Ophthalmic Solution and Bimatoprost 0.03% Ophthalmic Solution for Glaucoma and Ocular Hypertension. Completed, enrolled 597 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedApr 8, 2010
Enrollment StartMay 1, 2010
Primary CompletionApr 29, 2011
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 16.2 years ago
Interventions
Bimatoprost 0.03% Formulation B Ophthalmic Solutiondrug
One drop administered in each eye, every evening, for 12 weeks
Bimatoprost 0.03% Ophthalmic Solutiondrug
One drop administered in each eye, every evening, for 12 weeks